Plasma thiobarbituric acid-reactive substance levels in subclinical hypothyroidism

Medical Principles and Practice

Volumn 16, Issue 6, 2007, Pages 432-436

  Kebapcilar, Levent ^a   Akinci, Baris ^a   Bayraktar, Firat ^a   Comlekci, Abdurrahman ^a   Solak, Ahmet ^a   Demir, Tevfik ^a   Yener, Serkan ^a   Küme, Tuncay ^a   Yesil, Sena ^a  

^a DOKUZ EYLUL UNIVERSITY   (Turkey)

Author keywords

High sensitive C reactive protein; Subclinical hypothyroidism; Thiobarbituric acid reactive substance

Indexed keywords

C REACTIVE PROTEIN; LEVOTHYROXINE; LIPID; THIOBARBITURIC ACID REACTIVE SUBSTANCE; THYROTROPIN;

ADULT; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; EUTHYROIDISM; FEMALE; HORMONAL THERAPY; HUMAN; HYPOTHYROIDISM; LIPID BLOOD LEVEL; PROTEIN BLOOD LEVEL; STATISTICAL SIGNIFICANCE; THERAPY EFFECT; THIOBARBITURIC ACID REACTIVE SUBSTANCE BLOOD LEVEL; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; COHORT STUDIES; FEMALE; HUMANS; HYPOTHYROIDISM; LIPIDS; MIDDLE AGED; OXIDATIVE STRESS; THIOBARBITURIC ACID REACTIVE SUBSTANCES; THYROXINE;

EID: 35148817413     PISSN: 10117571     EISSN: None     Source Type: Journal    
DOI: 10.1159/000107747     Document Type: Article

References (26)

1. Palmieri EA, Fazio S, Lombardi G, Biondi B: Subclinical hypothyroidism and cardiovascular risk: a reason to treat? Treat Endocrinol 2004;3:233-244.
2. Vanderpump MP, Tunbridge WM, French JM, Appleton D, Bates D, Clark F, Grimley Evans J, Rodgers H, Tunbridge F, Young ET: The development of ischemic heart disease in relation to autoimmune thyroid disease in a 20-year follow-up study of an English community. Thyroid 1996;6:155-160.
3. Hak AE, Pols HA, Visser TJ, Drexhage HA, Hofman A, Witteman JC: Subclinical hypothyroidism is an independent risk factor for atherosclerosis and myocardial infarction in elderly women: the Rotterdam Study. Ann Intern Med 2000;132:270-278.
4. Rodondi N, Newman AB, Vittinghoff E, de Rekeneire N, Satterfield S, Harris TB, Bauer DC: Subclinical hypothyroidism and the risk of heart failure, other cardiovascular events, and death. Arch Intern Med 2005;165:2460-2466.
5. Duntas LH: Oxidants, antioxidants in physical exercise and relation to thyroid function. Horm Metab Res 2005;37:572-576.
6. Sattler W, Malle E, Kostner GM: Methodological approaches for assessing lipid and protein oxidation and modification in plasma and isolated lipoproteins. Methods Mol Biol 1998;110:167-191.
7. Walter MF, Jacob RF, Jeffers B, Ghadanfar MM, Preston GM, Buch J, Mason RP: Serum levels of thiobarbituric acid reactive substances predict cardiovascular events in patients with stable coronary artery disease: a longitudinal analysis of the PREVENT study. J Am Coll Cardiol 2004;44:1996-2002.
8. Miller M, Zhan M, Havas S: High attributable risk of elevated C-reactive protein level to conventional coronary heart disease risk factors: The Third National Health and Nutrition Examination Survey. Arch Intern Med 2005;165:2063-2068.
9. Buege JA, Aust SD: Lactoperoxidase-catalyzed lipid peroxidation of microsomal and artificial membranes. Biochim Biophys Acta 1976;444:192-201.
10. Lapenna D, Ciofani G, Pierdomenico SD, Giamberardino MA, Cuccurullo F: Reaction conditions affecting the relationship between thiobarbituric acid reactivity and lipid peroxides in human plasma. Free Radic Biol Med 2001;31:331-335.
11. Taddei S, Caraccio N, Virdis A, Dardano A, Versari D, Ghiadoni L, Ferrannini E, Salvetti A, Monzani F: Low-grade systemic inflammation causes endothelial dysfunction in patients with Hashimoto's thyroiditis. J Clin Endocrinol Metab 2006;91:5076-5082.
12. Mackness MI, Durrington PN, Mackness B: How high-density lipoprotein protects against the effects of lipid peroxidation. Curr Opin Lipidol 2000;11:383-388.
13. Sanguinetti SM, Brites FD, Fasulo V, Verona J, Elbert A, Wikinski RL, Schreier LE: HDL oxidability and its protective effect against LDL oxidation in type 2 diabetic patients. Diabetes Nutr Metab 2001;14:27-36.
14. Zago V, Sanguinetti S, Brites F, Berg G, Verona J, Basilio F, Wikinski R, Schreier L: Impaired high density lipoprotein antioxidant activity in healthy postmenopausal women. Atherosclerosis 2004;177:203-210.
15. Abbott CA, Mackness MI, Kumar S, Boulton AJ, Durrington PN: Serum paraoxonase activity, concentration, and phenotype distribution in diabetes mellitus and its relationship to serum lipids and lipoproteins. Arterioscler Thromb Vasc Biol 1995;15:1812-1818.
16. Mackness MI, Mackness B, Durrington PN, Connelly PW, Hegele RA: Paraoxonase: biochemistry, genetics and relationship to plasma lipoproteins. Curr Opin Lipidol 1996;7:69-76.
17. Milionis HJ, Tambaki AP, Kanioglou CN, Elisaf MS, Tselepis AD, Tsatsoulis A;Thyroid substitution therapy induces high-density lipoprotein-associated platelet-activating factor-acetylhydrolase in patients with subclinical hypothyroidism: a potential antiatherogenic effect. Thyroid 2005;15:455-460.
18. de Castro AV, Bononi AP, Aragon F, Padovani CR, Nogueira CR, Mazeto GM, Pimenta WP: Clinical and laboratory evaluation of hyperlipemic and hypothyroid patients. Arq Bras Cardiol 2001;76:119-126.
19. Duntas LH: Thyroid disease and lipids. Thyroid 2002;12:287-293.
20. Tan KC, Shiu SW, Kung AW: Effect of thyroid dysfunction on high-density lipoprotein subfraction metabolism: roles of hepatic lipase and cholesteryl ester transfer protein. J Clin Endocrinol Metab 1998;83:2921-2924.
21. Wahlqvist ML, Fidge NH, Lomas F: Lipoprotein composition in hypothyroidism. Clin Chim Acta 1977;77:269-274.
22. Thomas MK, Narang D, Lakshmy R, Gupta R, Naik N, Maulik SK: Correlation between inflammation and oxidative stress in normocholesterolemic coronary artery disease patients 'on' and 'off' atorvastatin for short time intervals. Cardiovasc Drugs Ther 2006;20:37-44.
23. Ozcan O, Cakir E, Yaman H, Akgul EO, Erturk K, Beyhan Z, Bilgi C, Erbil MK: The effects of thyroxine replacement on the levels of serum asymmetric dimethylarginine (ADMA) and other biochemical cardiovascular risk markers in patients with subclinical hypothyroidism. Clin Endocrinol (Oxf) 2005;63:203-206.
24. Tuzcu A, Bahceci M, Gokalp D, Tuzun Y, Gunes K: Subclinical hypothyroidism may be associated with elevated high-sensitive C-reactive protein (low grade inflammation) and fasting hyperinsulinemia. Endocr J 2005;52:89-94.
25. Christ-Crain M, Meier C, Guglielmetti M, Huber PR, Riesen W, Staub JJ, Muller B: Elevated C-reactive protein and homocysteine values: cardiovascular risk factors in hypothyroidism? A cross-sectional and a double-blind, placebo-controlled trial. Atherosclerosis 2003;166:379-386.
26. Hueston WJ, King DE, Geesey ME: Serum biomarkers for cardiovascular inflammation in subclinical hypothyroidism. Clin Endocrinol (Oxf) 2005;63:582-587.